安斯泰来对多样性的承诺

在安斯泰来，我们深知临床试验的多样性对于推动医疗进步、确保每个人都能从医疗创新中获益至关重要。We are committed to fostering an inclusive environment that reflects the diverse communities we serve.

To do this, we are committed to:

Engage Diverse Populations

Actively seek to include people from different racial, ethnic, gender, age and socioeconomic backgrounds in our clinical trials to make sure the results apply to all

Implement Inclusive Practices

Design our clinical trials to be accessible, culturally sensitive, and supportive to make participation easier

Work with Communities

Partner with community groups, healthcare providers and patient advocacy organizations to raise awareness about clinical trials, address barriers to participation, and build trust with patients and caregivers

Educate and Train Staff

Train our teams on the importance of diversity and equip them with the tools to engage and include everyone effectively

Advocate for Change

Join industry-wide efforts to remove barriers and make it easier to take part in clinical trials

By committing to these principles, we aim to enhance the quality and relevance of our clinical research, ultimately leading to better health outcomes for everyone.

提高临床试验多样性的重要性

Looking back through the history of clinical research, women, people of different racial and ethnic groups, and older adults were underrepresented. Sometimes, these groups were left out completely.

However, diseases, health conditions and treatments affect patient populations differently. For example:

Gastric (stomach) cancer occurs more often in Black, Asian and Latino populations than in Caucasians (white people)

Prostate cancer, the most common cancer in men, affects more Black men than those of any other racial or ethnic group.

Sjögren’s Syndrome is more common in women than in men

An older patient’s body may process medications differently than a younger patient’s body

Today, researchers know that it is important to include diverse groups of people in clinical trials. This includes different genders, races, ethnicities, and age groups. This inclusive approach helps researchers understand how diseases affect different people and how they respond to treatment.

To develop treatments that are safe and effective for everyone, diversity must be a priority in clinical trials.

了解参与临床试验的障碍

过去，全球临床研究中曾发生过不当行为和侵犯人权的案例。这促使出台了新的法律和伦理准则，以保护临床试验中的参与者。如今已经有了相关保护措施，确保所有临床试验参与者得到合乎伦理的对待。然而，许多人对临床研究和参与临床试验仍存有顾虑。尽管近期研究表明，来自代表性不足群体的民众愿意加入，但他们往往无法获得所需的信息和渠道。

Additional efforts to improve diversity in clinical trials

There are other important measures being taken to increase diversity and ensure scientifically representative clinical research. 包括：

1990

Mid 1990s

National Institutes of Health (NIH) requirement that clinical trials include racial and ethnic minorities, women and individuals of all ages

Mid 2010-2020 to Present

Study sponsors voluntarily providing data to help the FDA track the participation rates of females, males, children, the elderly, and different underrepresented groups

Est 2021

United Kingdom’s NHS Race and Health Observatory initiative that investigates and addresses race inequality in medicine

Early 2000s to Present

Food and Drug Administration (FDA) regulations and guidance to ensure diverse inclusion in clinical trials

2020 to Present

Industry-wide initiatives, such as PhRMA’s Equity Initiative in the United States

Present Time

Additional Resources

Resource

Learn more about PhRMA’s industry initiatives to enhance diversity in clinical trials

了解更多

Resource

Learn more about diversity in a clinical trials topics from the Center for Information and Study on Clinical Research Participation (CISCRP).

了解更多

查找您附近的安斯泰来临床试验

搜索可能适合您或您亲友的安斯泰来临床试验。

搜索试验

探索更多

谨供参考

本网站的目的是向患者及其家人和朋友、公众和医疗保健专业人员提供有关临床试验过程的教育和信息。此外，本网站还提供了有关安斯泰来临床试验的具体信息。请阅读完整的 安斯泰来透明度政策， 以了解本网站可提供的临床试验信息